Sino Biological Unveils Key Antigens for Upcoming Influenza Vaccine Development
In a significant advance for global health, Sino Biological, a leader in recombinant technology, has announced the launch of new antigens specifically designed for the 2026-2027 Northern Hemisphere influenza vaccine strains. This initiative comes in light of the recent recommendations from the World Health Organization (WHO), which identified influential strains that impact vaccine formulation.
The WHO has continuously monitored the evolution of influenza viruses and has made crucial recommendations to ensure effective vaccination. For the 2026-2027 season, the WHO highlighted the spread of A(H3N2) subclade K and certain B/Victoria lineage strains, indicating a shift in strain dominance which necessitated updates in the vaccine composition.
The H3N2 subclade K, identified as J.2.4.1, has emerged as the dominant influenza A strain since its detection in August 2025. Genetic mutations T135K and S144N in this strain allow it to evade immune responses, leading WHO to select A/Darwin/1454/2025 as the new reference virus. Similarly, the H1N1 component has been revised to A/Missouri/11/2025 to keep up with the current epidemiological trends. The B/Victoria strain has also seen a considerable increase in prevalence, rising from 6% to over 20% in various regions such as the U.S. and Hong Kong SAR. As a response, WHO recommended the inclusion of both B/Tokyo/EIS13-175/2025 and B/Pennsylvania/14/2025 strains.
To support influenza vaccine research and ensure preparedness against the upcoming flu season, Sino Biological has rolled out a comprehensive range of recombinant antigens for the new vaccine strains. This includes high-purity proteins such as HA Trimer (purity ≥90% verified by SEC-MALS), NA, and NP proteins derived from the identified strains. Dr. Rob Burgess, Chief Business Officer, expressed the company's mission to equip researchers with high-quality research tools promptly, especially as infectious diseases pose an ongoing threat to global health infrastructure.
Sino Biological's extensive product offerings span various scientific needs, catering to researchers involved in basic research, drug discovery, diagnostics, and vaccine development across more than 90 countries.
With the continuing evolution of viruses, the timely launch of these antigens not only illustrates Sino Biological's commitment to innovation within the biotechnology sector but also enhances overall public health preparedness. Having access to these antigenic materials early on can expedite vaccine research and improve outcomes in combating seasonal influenza. This proactive approach by Sino Biological is crucial as healthcare professionals worldwide gear up for the anticipated flu season, aiming to protect populations vulnerable to influenza infections.
Sino Biological continues to establish itself as a pivotal player in the fight against infectious diseases, leveraging its advanced recombinant technologies to provide essential tools for vaccine development. By addressing the needs highlighted by the WHO through timely antigen development, the company plays a vital role in ensuring preparedness against influenza outbreaks.
For further inquiries or partnership opportunities, reach out to Sino Biological at their official website.
Background on Influenza Vaccine Development
The WHO has continuously monitored the evolution of influenza viruses and has made crucial recommendations to ensure effective vaccination. For the 2026-2027 season, the WHO highlighted the spread of A(H3N2) subclade K and certain B/Victoria lineage strains, indicating a shift in strain dominance which necessitated updates in the vaccine composition.
The H3N2 subclade K, identified as J.2.4.1, has emerged as the dominant influenza A strain since its detection in August 2025. Genetic mutations T135K and S144N in this strain allow it to evade immune responses, leading WHO to select A/Darwin/1454/2025 as the new reference virus. Similarly, the H1N1 component has been revised to A/Missouri/11/2025 to keep up with the current epidemiological trends. The B/Victoria strain has also seen a considerable increase in prevalence, rising from 6% to over 20% in various regions such as the U.S. and Hong Kong SAR. As a response, WHO recommended the inclusion of both B/Tokyo/EIS13-175/2025 and B/Pennsylvania/14/2025 strains.
Sino Biological's Innovative Solutions
To support influenza vaccine research and ensure preparedness against the upcoming flu season, Sino Biological has rolled out a comprehensive range of recombinant antigens for the new vaccine strains. This includes high-purity proteins such as HA Trimer (purity ≥90% verified by SEC-MALS), NA, and NP proteins derived from the identified strains. Dr. Rob Burgess, Chief Business Officer, expressed the company's mission to equip researchers with high-quality research tools promptly, especially as infectious diseases pose an ongoing threat to global health infrastructure.
Sino Biological's extensive product offerings span various scientific needs, catering to researchers involved in basic research, drug discovery, diagnostics, and vaccine development across more than 90 countries.
Significance of the Development
With the continuing evolution of viruses, the timely launch of these antigens not only illustrates Sino Biological's commitment to innovation within the biotechnology sector but also enhances overall public health preparedness. Having access to these antigenic materials early on can expedite vaccine research and improve outcomes in combating seasonal influenza. This proactive approach by Sino Biological is crucial as healthcare professionals worldwide gear up for the anticipated flu season, aiming to protect populations vulnerable to influenza infections.
Conclusion
Sino Biological continues to establish itself as a pivotal player in the fight against infectious diseases, leveraging its advanced recombinant technologies to provide essential tools for vaccine development. By addressing the needs highlighted by the WHO through timely antigen development, the company plays a vital role in ensuring preparedness against influenza outbreaks.
For further inquiries or partnership opportunities, reach out to Sino Biological at their official website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.